Clinical Study

Safety and Efficacy proven up to Three years 0% Scaffold Thrombosis in both Indian and International Patients

Pre-Clinical Studies

Animal studies have shown higher safety score with MeRes100™ compared to first generation 150 microns BVS

MeRes100™ has shown less fibrin deposition (mean score= 0.00±0.00) when compared to 1st Gen BVS (mean score= 0.20±0.28). Inflammation score was also lesser with MeRes100™ (mean score= 0.15±0.10) when compared to 1st Gen BVS (mean score= 0.40±0.57)

Animal Studies have shown that artery returns to its natural shape post resorption of the MeRes100™ at 3 years

Images courtesy Skirball Research Institute. Data on File Meril Life Sciences Pvt. Ltd